Form 4: Centessa Pharmaceuticals Executive Exercises Options and Sells Shares

Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, exercised share options and sold a portion of the acquired shares on February 7 and February 10, 2025, according to a Form 4 filing.

Summary

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals plc, executed transactions involving the company's ordinary shares.
• On February 7, 2025, Anderson exercised options to acquire 30,526 ordinary shares at a price of $4.01 per share and then sold the same amount at a weighted average price of $19.0263.
• Following these transactions, Anderson directly owns 54,322 ordinary shares.
• On February 10, 2025, Anderson exercised options to acquire 429 ordinary shares at a price of $4.01 per share and then sold the same amount at a price of $18.99.
• Following these transactions, Anderson directly owns 54,322 ordinary shares.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 13, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a common tool used by corporate insiders to sell shares while avoiding accusations of insider trading.
• The size and frequency of insider transactions are often compared to those of peer companies to assess the overall health and sentiment surrounding a stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates any significant concerns.
• Employees are unlikely to be directly affected by these transactions.

Key Dates

Keywords

Centessa Pharmaceuticals, Karen M. Anderson, Form 4, share options, stock sale, Rule 10b5-1, CNTA, insider trading